If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Gfinity, Xpediator and Midatech Pharma
John Clarke, Chief Executive Officer, Gfinity (GFIN) talks about the multi-year agreement they have signed with Formula 1.
Gfinity (AIM: GFIN) is a world leading esports business. Created by gamers for the world's 2.2 billion gamers, Gfinity has a unique understanding of this fast-growing global community. It uses this expertise both to provide advisory services and to design, develop and deliver unparalleled experiences and winning strategies for game publishers, sports rights holders, commercial partners and media companies.
Stephen Blyth, Chief Executive Office of Xpediator (XPD) discusses their subsidiary Pall-Ex in Romania having delivered 3 million pallets since it was established in 2012.
Xpediator is a well-established international provider of freight management services. Established in 1988 by Stephen Blyth, the Group's international network of offices provides road, sea and air freight services, together with logistics and warehousing in the UK and Romania. The business offers integrated freight management within the supply chain logistics and fulfilment sector, through its three main areas: freight forwarding, logistics & warehousing and transport services. With headquarters in Braintree, Essex and country offices in nine CEE countries across 38 sites, the Group currently employs over 1,000 people and was successfully listed on London's AIM market in August 2017.
(Interview starts at 12 minutes 28 seconds)
Stephen Stamp, CEO, CFO of Midatech Pharma (MTPH) explains how the £3.8m they have raised will be used to progress their clinical programme and product pipeline.
Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on 'Making Medicines Better' by improving delivery of drugs in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment for life threatening diseases.
(Interview starts at 21 minutes 40 seconds)